
Opinion|Videos|December 28, 2023
Key Takeaways on Evolving Bladder Cancer Treatment Landscape
The expert panel concludes its discussion by providing key takeaways on the evolving bladder cancer treatment landscape following ESMO 2023.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants tentative approval to generic olaparib tablets across previously approved indications
2
Phase 3 trial launches of CAIX-targeted radiopharmaceutical for ccRCC
3
FDA grants priority review to talazoparib plus enzalutamide for HRR gene-altered mCSPC
4
Published data support PSMA-PET–guided selection for 177Lu-rosopatamab tetraxetan in mCRPC
5












